PRECISION BIOSCIENCES INC (DTIL)
US74019P2074 - Common Stock
Taking everything into account, DTIL scores 2 out of 10 in our fundamental rating. DTIL was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of DTIL have multiple concerns. While showing a medium growth rate, DTIL is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year DTIL has reported negative net income.
In the past year DTIL has reported a negative cash flow from operations.
DTIL had negative earnings in each of the past 5 years.
DTIL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -38.38%, DTIL is doing good in the industry, outperforming 62.29% of the companies in the same industry.
DTIL's Return On Equity of -325.11% is on the low side compared to the rest of the industry. DTIL is outperformed by 76.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.38% | ||
| ROE | -325.11% | ||
| ROIC | N/A |
ROA(3y)-33.23%
ROA(5y)-42.35%
ROE(3y)-181.14%
ROE(5y)-171.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DTIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DTIL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DTIL has been reduced compared to 1 year ago.
Compared to 5 years ago, DTIL has less shares outstanding
DTIL has a worse debt/assets ratio than last year.
2.2 Solvency
DTIL has an Altman-Z score of -4.34. This is a bad value and indicates that DTIL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DTIL (-4.34) is worse than 61.77% of its industry peers.
A Debt/Equity ratio of 1.19 is on the high side and indicates that DTIL has dependencies on debt financing.
DTIL has a Debt to Equity ratio of 1.19. This is in the lower half of the industry: DTIL underperforms 79.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.34 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
DTIL has a Current Ratio of 2.73. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
DTIL has a worse Current ratio (2.73) than 69.80% of its industry peers.
A Quick Ratio of 2.73 indicates that DTIL has no problem at all paying its short term obligations.
With a Quick ratio value of 2.73, DTIL is not doing good in the industry: 67.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.73 |
3. Growth
3.1 Past
The earnings per share for DTIL have decreased strongly by -79.64% in the last year.
Looking at the last year, DTIL shows a very strong growth in Revenue. The Revenue has grown by 94.14%.
Measured over the past years, DTIL shows a very strong growth in Revenue. The Revenue has been growing by 34.92% on average per year.
EPS 1Y (TTM)-79.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q47.95%
Revenue 1Y (TTM)94.14%
Revenue growth 3Y26.1%
Revenue growth 5Y34.92%
Revenue growth Q2Q-33.6%
3.2 Future
The Earnings Per Share is expected to grow by 15.49% on average over the next years. This is quite good.
The Revenue is expected to decrease by -0.16% on average over the next years.
EPS Next Y53.03%
EPS Next 2Y30.51%
EPS Next 3Y19.88%
EPS Next 5Y15.49%
Revenue Next Year-54.24%
Revenue Next 2Y-36.56%
Revenue Next 3Y-22.74%
Revenue Next 5Y-0.16%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DTIL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DTIL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DTIL's earnings are expected to grow with 19.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.51%
EPS Next 3Y19.88%
5. Dividend
5.1 Amount
No dividends for DTIL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRECISION BIOSCIENCES INC
NASDAQ:DTIL (5/3/2024, 7:00:01 PM)
After market: 10.36 -0.16 (-1.52%)10.52
-0.32 (-2.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap72.80M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.38% | ||
| ROE | -325.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.19 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-79.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y53.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)94.14%
Revenue growth 3Y26.1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y